A Phase 1/2 interventional study of Telaprevir and Peginterferon alfa-2b in Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 24 sites in 6 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-07-20.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.
Among the 39 studies testing telaprevir in Hepatitis C, this one is the 15th largest by enrollment, is one of 5 that started in 2013, is the only one in phase 1/2, and was the 33rd registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 9 · Phase 3 13 · Phase 4 5
First in 2005; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 30 across the 39 interventional studies. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 39 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
19 studies in Hepatitis C by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 19 finished, 9 (47%) have results posted.
Among the 19 studies in Hepatitis C by Vertex Pharmaceuticals Incorporated, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2013, is one of 2 in phase 1/2, and was the 18th registered.
Vertex Pharmaceuticals Incorporated’s Hepatitis C studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing telaprevir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 19 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, efficacy, and pharmacokinetics in a carefully monitored cohort of pediatric subjects infected with hepatitis C virus (HCV) on a telaprevir-based regimen in Part A and with dose adjustments if needed before Part B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
telaprevir + Peginterferon alfa-2b + Ribavirin
Drug: Telaprevir · Drug: Peginterferon alfa-2b · Drug: Ribavirin
100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
Also known as: PegIntron®
200-mg capsules or 40-mg/mL solution for oral administration
Also known as: Rebetol®
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents administered during the course of the study.
Time frame: Baseline up to Week 52
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (less than \[\<\] lower limit of quantification) at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/High Pure System (HPS) RNA assay version 2.0. The lower limit of quantification was 25 international units per milliliter (IU/mL).
Time frame: 12 weeks after last planned dose of study drug (up to Week 60)
Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)
SVR24 was defined as an undetectable HCV RNA Levels (\< lower limit of quantification) at 24 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.
Time frame: 24 weeks after last planned dose of study drug (up to Week 72)
Percentage of Participants With Rapid Virologic Response (RVR)
The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. RVR was defined as an undetectable HCV RNA (\<lower limit of quantification) 4 weeks after the start of study treatment.
Time frame: Week 4
Percentage of Participants With Extended Rapid Virologic Response (eRVR)
The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. eRVR was defined as an undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.
Time frame: Week 4 and Week 12
Percentage of Participants With Undetectable HCV RNA at Week 12
The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.
Time frame: Week 12
Percentage of Participants With On-treatment Virologic Failure
On treatment virologic failure was defined as meeting any futility rule or completing assigned treatment duration and having detectable HCV RNA at EOT. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Futility rules: 1) HCV RNA \>1000 IU/mL at Week 4; 2) HCV RNA \>1000 IU/mL at Week 12; 3) Detectable HCV RNA after Week 12 to end of treatment.
Time frame: Baseline up to Week 48
Percentage of Participants With Virologic Relapse
The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Viral relapse was defined as having detectable HCV at follow-up in participants who had HCV RNA less than (\<) lower limit of quantification (LLOQ) at planned EOT.
Time frame: 12 weeks after planned EOT (up to Week 60)
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by age.
Time frame: Baseline, On treatment (up to Week 48)
Maximum Plasma Concentration (Cmax) of Telaprevir
Cmax was measured for telaprevir only.
Time frame: Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7
Time to Reach Maximum Plasma Concentration (Tmax) of Telaprevir
Tmax was measured for telaprevir only.
Time frame: Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7
Area Under the Plasma Concentration Versus Time Curve (AUC) of Telaprevir
AUC was measured for telaprevir only. AUC 0-t last was defined as the area under the concentration-time curve from the time of dosing to the last measurable concentration. AUC 0-12 hour (AUC 0-12h) was calculated by respecifying predose concentrations as 12 hour concentrations. AUC 0-24h was calculated as AUC 0-12h multiplied by 2. Dose adjusted AUC (AUC 0-24h_Adj) was calculated by multiplying AUC 0-24h by the dose adjustment factor to obtain projected exposures in participants who were misdosed. Data were presented for AUC 0-t last, AUC 0-12h, AUC 0-24h, AUC 0-24h_Adj.
Time frame: Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7
Elimination Half-Life (T1/2) of Telaprevir
T1/2 was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
Time frame: Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7
| Milestone | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| Started | 13 | 19 | 10 |
| Completed | 13 | 18 | 8 |
| Not completed | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 1 |
AE: any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents administered during the course of the study.
| participants | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| Participants with SAEs | 0 | 0 | 1 |
| Participants with AEs | 13 | 18 | 10 |
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (less than \[\<\] lower limit of quantification) at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/High Pure System (HPS) RNA assay version 2.0. The lower limit of quantification was 25 international units per milliliter (IU/mL).
| percentage of participants | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12) | 69.2 | 89.5 | 40.0 |
SVR24 was defined as an undetectable HCV RNA Levels (\< lower limit of quantification) at 24 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.
No measurements were reported for this outcome.
The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. RVR was defined as an undetectable HCV RNA (\<lower limit of quantification) 4 weeks after the start of study treatment.
| percentage of participants | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| Percentage of Participants With Rapid Virologic Response (RVR) | 69.2 | 73.7 | 70.0 |
The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. eRVR was defined as an undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.
| percentage of participants | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| Percentage of Participants With Extended Rapid Virologic Response (eRVR) | 61.5 | 73.7 | 60.0 |
The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.
| percentage of participants | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| Percentage of Participants With Undetectable HCV RNA at Week 12 | 69.2 | 89.5 | 70.0 |
On treatment virologic failure was defined as meeting any futility rule or completing assigned treatment duration and having detectable HCV RNA at EOT. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Futility rules: 1) HCV RNA \>1000 IU/mL at Week 4; 2) HCV RNA \>1000 IU/mL at Week 12; 3) Detectable HCV RNA after Week 12 to end of treatment.
| percentage of participants | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| Percentage of Participants With On-treatment Virologic Failure | 15.4 | 5.3 | 30.0 |
The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Viral relapse was defined as having detectable HCV at follow-up in participants who had HCV RNA less than (\<) lower limit of quantification (LLOQ) at planned EOT.
| percentage of participants | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| Percentage of Participants With Virologic Relapse | 0 | 0 | 0 |
Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by age.
| participants | Overall Participants |
|---|---|
| Baseline (n = 41) | 2 |
| On treatment (n = 6) | 6 |
Cmax was measured for telaprevir only.
| nanogram per milliliter (ng/mL) | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Telaprevir | 4310 ± 1160 | 5050 ± 884 | 4060 ± 1500 |
Tmax was measured for telaprevir only.
| hours (h) | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Telaprevir | 4.00 (1.92 to 8.00) | 4.00 (1.98 to 6.02) | 4.00 (1.50 to 8.00) |
AUC was measured for telaprevir only. AUC 0-t last was defined as the area under the concentration-time curve from the time of dosing to the last measurable concentration. AUC 0-12 hour (AUC 0-12h) was calculated by respecifying predose concentrations as 12 hour concentrations. AUC 0-24h was calculated as AUC 0-12h multiplied by 2. Dose adjusted AUC (AUC 0-24h_Adj) was calculated by multiplying AUC 0-24h by the dose adjustment factor to obtain projected exposures in participants who were misdosed. Data were presented for AUC 0-t last, AUC 0-12h, AUC 0-24h, AUC 0-24h_Adj.
| hours*nanogram per milliliter (h*ng/mL) | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| AUC 0-t last | 39900 ± 11300 | 43300 ± 9480 | 35300 ± 12000 |
| AUC 0-12h | 39900 ± 11300 | 44100 ± 9020 | 35300 ± 12000 |
| AUC 0-24h | 79900 ± 22700 | 88100 ± 18000 | 70600 ± 24100 |
| AUC 0-24h_Adj | 95700 ± 29800 | 88600 ± 19200 | 76300 ± 22800 |
T1/2 was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
No measurements were reported for this outcome.
Collected over Baseline up to Week 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | — | 0/13 (0%) | 13/13 (100%) |
| Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | — | 0/19 (0%) | 18/19 (94.7%) |
| Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | — | 1/10 (10%) | 10/10 (100%) |
| Event | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| InfectionInfections and infestations | 0/13 | 0/19 | 1/10 |
| Event | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV |
|---|---|---|---|
| HeadacheNervous system disorders | 8/13 | 16/19 | 6/10 |
| PyrexiaGeneral disorders | 7/13 | 11/19 | 8/10 |
| VomitingGastrointestinal disorders | 8/13 | 12/19 | 6/10 |
| NauseaGastrointestinal disorders | 7/13 | 5/19 | 5/10 |
| FatigueGeneral disorders | 7/13 | 5/19 | 3/10 |
| AlopeciaSkin and subcutaneous tissue disorders | 7/13 | 1/19 | 0/10 |
| PainGeneral disorders | 2/13 | 4/19 | 5/10 |
| Abdominal painGastrointestinal disorders | 5/13 | 3/19 | 1/10 |
| DizzinessNervous system disorders | 5/13 | 5/19 | 0/10 |
| Anal pruritusGastrointestinal disorders | 4/13 | 4/19 | 3/10 |
Full analysis set (FAS) included all enrolled participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Total |
|---|---|---|---|---|
| Mean | 14.9 ± 2.06 | 10.2 ± 1.57 | 4.9 ± 0.88 | 10.4 ± 4.05 |
| Sex: Female, Male(Participants) | Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Cohort 3 (3-6 Years): Telaprevir + Peg-IFN-alfa-2b + RBV | Total |
|---|---|---|---|---|
| Female | 11 | 13 | 4 | 28 |
| Male | 2 | 6 | 6 | 14 |
The record gives a start of Jan 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telaprevir · Peginterferon alfa-2b · Ribavirin
Vertex Pharmaceuticals Incorporated →